Advancing Patient Care in RA

Introduction

Pathogenic Pathways in RA

Approved and Emerging Biological Therapies

Pleiotropic Biological Effects of TNF and IL-6

Unmet Needs in RA

Pleiotropic Effects of IL-6 in RA

IL-6 Signaling Pathway: Classic Signaling

IL-6 Signaling Pathway: Levels of Inhibition

IL-6 Signaling Pathway: Trans Signaling

Clinical Signature of IL-6

Agents Targeting the IL-6 Signaling Pathway

Tocilizumab: ADACTA

Sarilumab: MOBILITY and TARGET

Sarilumab: MONARCH

Sirukumab Trial Program

Sirukumab: SIRROUND-T

Sirukumab: SIRROUND-LTE

Sirukumab: SIRROUND-D

Sirukumab: SIRROUND-H

Safety Profile of Anti-IL-6 Biologics

Biomarkers of Joint Damage: Effect of New Anti-IL-6 Biologics

CVD Risk in RA

CVD Risk in RA: Tocilizumab

PROs and Depression

Potential Differences Between IL-6 Inhibitors: MOA

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)